About BeyondSpring (NASDAQ:BYSI)
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BYSI
CUSIPN/A
Phone646-528-4184
Debt
Debt-to-Equity RatioN/A
Current Ratio6.75%
Quick Ratio6.75%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.23 per share
Price / Book25.28
Profitability
EPS (Most Recent Fiscal Year)($4.40)
Net Income$-91,760,000.00
Net MarginsN/A
Return on Equity-224.65%
Return on Assets-208.02%
Miscellaneous
Employees25
Outstanding Shares22,460,000
BeyondSpring (NASDAQ:BYSI) Frequently Asked Questions
What is BeyondSpring's stock symbol?
BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."
How were BeyondSpring's earnings last quarter?
BeyondSpring (NASDAQ:BYSI) released its quarterly earnings results on Tuesday, April, 3rd. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by $0.06. View BeyondSpring's Earnings History.
When is BeyondSpring's next earnings date?
What price target have analysts set for BYSI?
4 Wall Street analysts have issued 1-year price objectives for BeyondSpring's shares. Their forecasts range from $50.00 to $60.00. On average, they expect BeyondSpring's share price to reach $54.50 in the next year. View Analyst Ratings for BeyondSpring.
What are Wall Street analysts saying about BeyondSpring stock?
Here are some recent quotes from research analysts about BeyondSpring stock:
- 1. According to Zacks Investment Research, "BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. " (4/5/2018)
- 2. Maxim Group analysts commented, "BeyondSpring reported 4Q17 with a net loss of $16.5M and ended the period with $30.6M in cash. Operating expenses for the year were $98M but included $42.3M for the remaining interest in Plinabulin and $18M in stock-based compensation. We estimate the company has runway into late 2018 and through the next catalysts." (4/3/2018)
Who are some of BeyondSpring's key competitors?
Some companies that are related to BeyondSpring include ImmunoGen (IMGN), Immuron (IMRN), Myovant Sciences (MYOV), G1 Therapeutics (GTHX), TherapeuticsMD (TXMD), Apellis Pharmaceuticals (APLS), Endo International (ENDP), WAVE Life Sciences (WVE), Theravance Biopharma (TBPH), PTC Therapeutics (PTCT), Mallinckrodt (MNK), Revance Therapeutics (RVNC), Dynavax Technologies (DVAX), Epizyme (EPZM), TG Therapeutics (TGTX), Retrophin (RTRX), Intra-Cellular Therapies (ITCI) and CytomX Therapeutics (CTMX).
Who are BeyondSpring's key executives?
BeyondSpring's management team includes the folowing people:
- Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 47)
- Mr. Edward Dongheng Liu, Chief Financial Officer
- Ms. Amy Yang, Controller
- Dr. Ramon W. Mohanlal M.D., Ph.D., MBA, Chief Medical Officer of BeyondSpring US (Age 60)
- Dr. G. Kenneth Lloyd Ph.D., Chief Scientific Officer of BeyondSpring US (Age 74)
When did BeyondSpring IPO?
(BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO.
Has BeyondSpring been receiving favorable news coverage?
News articles about BYSI stock have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BeyondSpring earned a news sentiment score of 0.15 on Accern's scale. They also assigned press coverage about the company an impact score of 46.40 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of BeyondSpring?
Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BeyondSpring's stock price today?
One share of BYSI stock can currently be purchased for approximately $31.10.
How big of a company is BeyondSpring?
BeyondSpring has a market capitalization of $698.38 million. The company earns $-91,760,000.00 in net income (profit) each year or ($4.40) on an earnings per share basis. BeyondSpring employs 25 workers across the globe.
How can I contact BeyondSpring?
BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 646-528-4184 or via email at [email protected]
MarketBeat Community Rating for BeyondSpring (BYSI)
MarketBeat's community ratings are surveys of what our community members think about BeyondSpring and other stocks. Vote "Outperform" if you believe BYSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BYSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
BeyondSpring (NASDAQ:BYSI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for BeyondSpring in the last 12 months. Their average twelve-month price target is $54.50, suggesting that the stock has a possible upside of 75.24%. The high price target for BYSI is $60.00 and the low price target for BYSI is $50.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $54.50 | $54.50 | $54.50 | $50.6667 |
| Price Target Upside: | 75.24% upside | 106.83% upside | 87.22% upside | 31.91% upside |
BeyondSpring (NASDAQ:BYSI) Consensus Price Target History
BeyondSpring (NASDAQ:BYSI) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
BeyondSpring (NASDAQ:BYSI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
BeyondSpring (NASDAQ BYSI) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 1.25%
BeyondSpring (NASDAQ BYSI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
BeyondSpring (NASDAQ BYSI) News Headlines
| Source: |
|
BeyondSpring (NASDAQ:BYSI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
BeyondSpring (NASDAQ:BYSI) Income Statement, Balance Sheet and Cash Flow Statement
BeyondSpring (NASDAQ BYSI) Stock Chart for Sunday, April, 22, 2018
Loading chart…
